Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2021-11-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company receiving an invention patent certificate from the Japanese Patent Office. It contains no financial data, no mention of financial results, no regulatory filings related to financial performance, and no shareholder meeting information. It is a corporate announcement about intellectual property rights. Given the content and length (497 characters), it does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is also not related to management changes, voting results, or capital changes. The best fitting category is Regulatory Filings (RNS), which covers miscellaneous corporate announcements that do not fit other categories.
2021-11-08 Chinese
第三届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the second meeting of the third Supervisory Board of Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It specifically states that the Supervisory Board reviewed and approved the company's 2021 third quarter report, confirming the report's compliance with laws and regulations and its accuracy. The document itself is an announcement of the meeting resolution and the approval of the quarterly report, not the quarterly report itself. The document length is short (625 characters), and it serves as a formal disclosure of the meeting outcome and approval, not containing the actual financial data or detailed report content. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not constitute the full report.
2021-10-25 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司2021 年第三季度报告" which translates to "Xiamen Ed Bio-pharmaceutical Technology Co., Ltd. 2021 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, shareholder information, and notes on financial performance for the third quarter of 2021. The document is approximately 15,000 characters long and includes substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-25 Chinese
第三届董事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the company's third board meeting, specifically approving the 2021 third quarter report. It states the meeting details, voting results, and references the full quarterly report being available on an external regulatory website. The document itself does not contain the financial statements or substantive financial data of the quarterly report but merely announces the approval and availability of the report elsewhere. The document length is short (587 characters), consistent with an announcement rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS) since it is an official announcement related to a board meeting and report approval but does not contain the report itself or detailed financial data.
2021-10-25 Chinese
关于独立董事取得独立董事资格证书的公告
Board/Management Information Classification · 95% confidence The document is a company announcement regarding independent directors obtaining their qualification certificates. It references board meetings, shareholder meetings, and compliance with Shenzhen Stock Exchange regulations about independent directors' qualifications. There is no financial data, no report attached or referenced as being published, and no mention of financial results or filings. The content is about board/management information, specifically about independent directors' qualifications and appointments. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and focused on management qualifications, not a report or announcement of voting results or regulatory filings.
2021-09-30 Chinese
关于监事会完成换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the completion of the supervisory board (监事会) re-election at Xiamen Aide Bio-Pharmaceutical Technology Co., Ltd. It details the election of new supervisors, their qualifications, and the departure of previous supervisors. There is no financial data, no mention of annual or interim reports, no audit information, and no regulatory certifications. The content focuses on changes in the company's supervisory board members, which falls under management or board information. Given the nature of the announcement about board member changes, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not a report publication announcement or a certification. Confidence is high due to clear content about board changes.
2021-08-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.